Medicine
Elrexfio 44 mg/1.1 mL injection
Elrexfio 44 mg/1.1 mL injection is a prescription medicine containing Elranatamab for subcutaneous use, marketed by US Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store refrigerated at 2 °C to 8 °C (36 °F to 46 °F) in the original carton…
Key facts
- Active ingredient (INN)
- Elranatamab
- Brand
- Elrexfio
- Strength
- 44 mg/1.1 mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Marketing authorisation holder
- US Pharmaceuticals
- Manufacturer
- US Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store refrigerated at 2 °C to 8 °C (36 °F to 46 °F) in the original carton until time of use to protect from light. Do not freeze or shake the vial or carton.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 15 August 2023
- Identifiers
- RxCUI 2644885, 2644891DailyMed set ID aa044060-5b4b-4692-bf0f-9a50e140b10eNDC 63539-252Application BLA761345
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
No pack sizes are recorded. Pack size and quantity are confirmed on the quote.
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Elranatamab 44 mg/1.1 mL injection.
Other strengths and forms of Elranatamab
Clinical summary
Elranatamab is a prescription medicine indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, among other approved uses. MedsAcross supplies Elranatamab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about ElranatamabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Elrexfio prescribing information (Pfizer Laboratories) · U.S. National Library of Medicine, DailyMed
- Elrexfio: European public assessment report (EPAR) · European Medicines Agency
Need Elrexfio 44 mg/1.1 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.